Longevity of implantable cardioverter defibrillators: a comparison among manufacturers and over time

Simon von Gunten†, Beat A. Schaer†*, Sing-Chien Yap, Tamas Szili-Torok, Michael Kühne, Christian Sticherling, Stefan Osswald, and Dominic A.M.J. Theuns

Aims

Longevity of implantable cardioverter defibrillators (ICDs) is crucial for patients and healthcare systems as replacements impact on infection rates and cost-effectiveness. Aim was to determine longevity using very large databases of two teaching hospitals with a high number of replacements and a rather homogeneous distribution among manufacturers.

Methods and results

The study population consists of all patients in whom an ICD was inserted in. All ICD manufacturers operating in Switzerland and the Netherlands and all implanted ICDs were included. Implantable cardioverter defibrillator replacements due to normal battery depletion were considered events, and other replacements were censored. Longevity was assessed depending on manufacturers, pacing mode, implant before/after 2006, and all parameters combined. We analysed data from 3436 patients in whom 4881 ICDs [44.2% VVI-ICDs, 27.4% DDD-ICDs, 26.3% cardiac resynchronization therapy (CRT)-ICDs, 2.0% subcutaneous ICDs] were implanted. The four major manufacturers had implant shares between 18.4 and 31.5%. Replacement due to battery depletion (27.4%) was performed for 1339 ICDs. Patient survival at 5 years was 80.1%. Longevity at 5 years improved in contemporary compared with elderly ICDs [63.9–80.6% across all ICDs, of 73.7–92.1% in VVIs, 58.2–76.1% in DDDs, and of 47.1–66.3% in CRT defibrillators, all P value < 0.05]. Remarkable differences were seen among manufacturers, and those with better performance in elderly ICDs were not those with better performance in contemporary ones.

Conclusion

Implantable cardioverter defibrillator longevity increased in contemporary models independent of manufacturer and pacing mode. Still, significant differences exist among manufacturers. These results might impact on device selection.

Keywords

Longevity • Implantable cardioverter-defibrillator • Survival • Cardiac resynchronization therapy

Introduction

In selected patients, implantable cardioverter defibrillators (ICDs) are considered standard of care for primary and secondary preventions of sudden cardiac death.1–3 Devices reduce morbidity and mortality due to efficient termination of ventricular tachyarrhythmias. Yet undesired factors such as complications during and early after implantation,3 deterioration in quality of life,4,6 lead failure,1 and advisories5 are increasingly identified. The most disturbing element for patients, apart from repeated inappropriate shocks,7 however, is the necessity of a surgical procedure for ICD replacement due to premature or even timely battery depletion. Besides the cost of the procedure, there is the risk of periprocedural complications such as damage to the leads, bleeding, and infections.8,9

During the past decade, several studies on ICD longevity have been published.10–20 With the exception of one large series,18 all studies included < 1300 ICDs and the number of actually replaced ICDs was low, thus compromising the significance of the results. In addition, analyses were performed only among different manufacturers, not accounting for temporal trends in longevity between
What’s new?

- Several studies on implantable cardioverter defibrillator (ICD) longevity have been published. Except one, all studies included <1300 ICDs and the number of replaced ICDs was low, thus compromising the significance of results. This one is a study with the largest number of ICDs included so far.
- It shows a rather homogenous distribution of ICDs from the four largest manufacturers (St. Jude Medical 31.5%, Biotronik 25.0%, Boston Scientific 19.4%, Medtronic 18.4%) compared with earlier studies with much more skewed distributions.
- Previous studies showed minor differences between manufacturers, while this study, especially in more contemporary ICDs, demonstrated huge differences. Longevity at 6 years in cardiac resynchronization therapy-ICDs, e.g. was 97.6% with the best manufacturer, compared with 46.3% with the second best.

different models. Overall, it was confirmed that single-chamber defibrillators (VVI-ICDs) have better longevity than dual-chamber defibrillators (DDD-ICDs) and the latter a better one than cardiac resynchronization therapy defibrillators (CRT-Ds).

In contrast, results regarding longevity advantages of one manufacturer as against another were heterogeneous and sometimes even contradictory. Nevertheless, positive results have been used by some manufacturers for advertising campaigns in major electrophysiological journals.

The aim of this study was to perform a comprehensive analysis of longevity in a large series of ICDs not only with respect to different manufacturers, but also to different device models, pacing mode and to determine temporal trends of ICD longevity.

Methods

The study population consists of all consecutive patients in whom an ICD was implanted at the Erasmus Medical Center, Rotterdam, the Netherlands and at the University of Basel Hospital, Basel, Switzerland. The implant period encompasses from March 1994 to January 2014. Some of these patients and ICDs have already been included in two previous studies. As this study is an analysis of all ICD implants in both hospitals, we still considered these data for the present study.

Baseline characteristics of the patients and details of follow-up visits were recorded prospectively, as well as data regarding implanted ICD, such as manufacturer, device model, and pacing mode (single chamber, dual chamber, CRT). Date of last access to the database was 31 May 2014 for patients at the Erasmus Medical Center, Rotterdam and 30 June 2014 for patients at the University of Basel Hospital.

ICD replacements due to normal battery depletion, a so-called elective replacement indication (ERI), were considered events. Service time in months was calculated as the difference between implant date and replacement date or between replacement date and replacement date, as appropriate. In all other replacement settings such as upgrade, advisory, or removal for infection, the device was censored at the date of the procedure. Implantable cardioverter defibrillators still in service were censored at the date of last database access. Implantable cardioverter defibrillators still in service but lost to follow-up were censored at the date of last follow-up. Implantable cardioverter defibrillators of patients who died or were transplanted were censored at the date of these corresponding events. Figure 1 displays a flow chart of both patients and ICDs.

All manufacturers of ICDs ever operating in the two countries and all their ICDs used in the two hospitals were included. These were in alphabetical order: Biotronik (Berlin, Germany), Boston Scientific (earlier Guidant; Marlborough, MA), Cameron Health (San Clemente, CA), Intermedics (formerly in Le Locle, Switzerland), Medtronic (Minneapolis, MN), St. Jude Medical (St. Paul, MN), and Sorin (earlier ELA, Milano, Italy).

For the purpose of this article, the term longevity is used for device longevity and the term survival for patient survival.

The first analysis was performed across all ICDs of a given manufacturer, and longevity was compared. The second analysis was performed across different pacing modes, wherefore all manufacturers were merged and longevity was compared between pacing modes. The third analysis was performed across ICDs according to pacing mode in between individual manufacturers. For the fourth analysis, a ranking of longevity at the time points 4 and 5 years was performed and a corresponding chart of the best five and worst three devices was made. An analysis across ICDs with a similar production year grouped together was also performed here. Finally, a comparison of longevity across manufacturers according to pacing mode of ICDs implanted before 2006 and thereafter was performed. This time point was chosen as it was close to the median of all devices. No individual analyses were performed in those devices with <20 implants.

In both hospitals, an institutional review board approval was not required as the study was designed as an analysis of retrospective registry data. Patient information was de-identified in the merged Excel file that was used for all analyses.

Kaplan–Meier method was used to determine longevity, and differences were compared with log-rank testing. A P value of <0.05 was considered as statistically significant. All statistical analyses were performed using IBM SPSS software, version 22.

Results

We analysed data from 3436 patients [median age 62 years (IQR 52–70)] in whom 4881 ICDs have been implanted. Important baseline characteristics of the patients are shown in Table 1. During a follow-up of median 53 months (IQR 24–87), 822 (23.9%) patients died. This results in a 4-, 5-, and 10-year cumulative survival of 83.3, 80.1, and 59.1%, respectively. The corresponding Kaplan–Meier curve (Supplementary material online, Figure S1) indicates a linear mortality rate. Appropriate ICD therapy was delivered to 972 patients (28%).

Overall, 2158 (44.2%) VVI-ICDs, 1340 (27.4%) DDD-ICDs, 1284 (26.3%) CRT-ICDs, and 99 (2.0%) subcutaneous ICDs were inserted. In Table 2, details on manufacturers and pacing modes are presented. The percentages of ICDs used from the different manufacturers in a downward frequency are as follows: St. Jude Medical 31.5%, Biotronik 25.0%, Boston Scientific 19.4%, Medtronic 18.4%, Sorin ELA 3.2%, Cameron Health 2.0%, and Intermedics 0.4%. In the Supplementary material online, Table S1, all ICD models are displayed in detail. As shown in Figure 1, 1339 ICDs were replaced for ERI (27.4%, range 1–5 per patient) and 206 (4.6%) for other reasons.
Overall longevity, is shown in the Supplementary material online, Figure S2. It was 85.1% at 4 years and 69.8% at 5 years. Longevity before 2006 (2198 ICDs, 45%) and thereafter (2683 ICDs, 55%) was compared. These overall values at 5 and 6 years for VVI-ICDs, DDD-ICDs, and CRT-Ds were 80.1 and 62.7, 62.0 and 43.4, and 56.3 and 27.4%, respectively. The difference according to pacing modes before and after 2006 is depicted in the Supplementary material online, Figure S3. Figures 2–5 show the comparisons of longevity according to manufacturers in the two implant periods before and after 2006, overall as well in the different pacing modes.

Overall, cumulative longevity markedly improved from 63.9 to 80.6% at 5 years and from 44.9 to 61.6% at 6 years (P ≤ 0.001). The same holds true for different pacing modes (all P ≤ 0.001). On the level of manufacturers, intra- as well as intermanufactural improvement was diverse and occasionally even remarkable. Whereas in the early period, usually Medtronic ICDs had the best longevity, this changed to Boston Scientific ICDs in contemporary devices. Boston Scientific ICDs exhibited an excellent, sometimes even 100% longevity, independent of pacing mode (see Table 3 for more details).

The Supplementary material online, Table S2, presents the charts of the five longest lasting and the three shortest lasting devices at the time points of 4 and 5 years, according to pacing mode. Medtronic held 10/30 positions in the longest lasting charts, Biotronik and Boston Scientific both 8/18 in the shortest lasting charts. The Supplementary material online, Tables S3 and S4, depicts longevity of ICD with a similar year of production and a comprehensive 5-year longevity of all ICD models.

Comparison with other studies regarding differences among manufacturers

Of the nine studies on overall longevity, only three provided reliable data in a larger group of patients and devices. 13,15,18

Discussion

This article represents the largest study on ICD longevity so far and includes all major manufacturers in a reasonably balanced proportion. Although all manufacturers have improved on longevity of their devices, large differences in longevity still exist. Before 2006, Medtronic VVI-ICDs, Medtronic DDD-ICDs, and St. Jude Medical CRT-Ds exhibited the best longevity. In the current era (i.e. after 2006), however, Boston Scientific ICDs outperformed all other manufacturers with regard to longevity. In spite of these partly remarkable improvements, survival of patients is better than ICD longevity and not vice versa as should be the case.

Figure 1 Flow chart of patients and ICDs.
All cover an extensive implant period of 13–21 years and therefore report on a vast range of ICD models. Superior longevity of VVI pacing mode (median longevity 6–7.3 years) over DDD pacing mode (5–5.7 years) and over CRT pacing mode (median longevity 4.2–5.2 years) is consistently reported, and these differences can be explained primarily by the increasing percentage of pacing. Main analyses were carried out by lumping together all ICDs by a given manufacturer independently of pacing mode and model. Medtronic excelled throughout with median longevities from 5.8 to 7.6 years. Runners-up were Boston Scientific and

### Table 1 Baseline characteristics of the 3436 patients

| Characteristic                        | Value       |
|---------------------------------------|-------------|
| Male gender                          | 2721 (79%)  |
| Age (mean ± SD)                       | 59 ± 14     |
| Follow-up (mean ± SD)                 | 60.3 ± 44.4 |
| Ejection fraction (mean ± SD)         | 32 ± 13     |
| QRS width (mean ± SD)                 | 127 ± 35    |
| Primary prevention                    | 1975 (57%)  |
| Ischaemic cardiomyopathy              | 2525 (74%)  |
| Myocardial infarction                 | 1825 (53%)  |
| Percutaneous coronary intervention    | 1069 (31%)  |
| Coronary artery bypass                | 769 (22%)   |
| Diabetes mellitus                     | 694 (20%)   |
| Creatinine level (μmol/L, mean ± SD)  | 103 ± 69    |
| NYHA Class I                          | 792 (23%)   |
| NYHA Class II                         | 1680 (49%)  |
| NYHA Class III                        | 907 (27%)   |
| NYHA Class IV                         | 39 (1%)     |
| ACE/ARB therapy                       | 2640 (77%)  |
| Beta-blocker therapy                  | 2621 (76%)  |
| Diuretic therapy                      | 2029 (59%)  |
| Statin therapy                        | 1978 (58%)  |
| Amiodarone therapy                    | 685 (20%)   |
| Digoxin therapy                       | 461 (13%)   |

SD, standard deviation; ACE, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker.

### Table 2 Manufacturers, ICD, pacing modes (upper row) and replaced ICDs (lower row), shown in alphabetical order

| Manufacturer   | VVI | DDD | CRT | Total | % Replaced |
|----------------|-----|-----|-----|-------|------------|
| Biotronik      | 645 | 346 | 228 | 1219  | 24.5%      |
| Boston Scientific | 413 | 275 | 259 | 947   | 31.8%      |
| Intermedics    | 21  | 0   | 0   | 21    | 90.5%      |
| Medtronic      | 449 | 182 | 267 | 898   | 39.6%      |
| Sorin ELA      | 10  | 144 | 4   | 158   | 19.2%      |
| Total Devices  | 2158| 1340| 1284| 4782  | 31.0%      |
| Replaced       | 557 | 455 | 316 | 1328  | 27.8%      |

ICD, implantable cardioverter defibrillator; VVI, single-chamber ICD; DDD, dual-chamber ICD; CRT, cardiac resynchronization therapy ICD.

### Figure 2 Comparison of longevity according to manufacturers (total n = 4881, before 2006 n = 2198, after 2006 n = 2683).
St. Jude Medical (5–5.4 and 5–5.8 years, respectively), with Bio-
tronik being at the tail end (4.6–4.7 years). Sorin ICDs were
incorporated in only one study. Even though these studies are
not without their merits, one of their major limitations lies in
the very skewed range of implant shares of the different manufac-
turers [6–61% in (10), 6–49% in (15), 18–49% in (12)]. In the
present study, with the largest numbers of ICDs implanted, this
range was much smaller (20–34%), which makes this analysis
more robust.

As one can appreciate by looking at data of longevity analysed ei-
ther by lumping together all ICDs of different manufacturers or by
comparing manufacturers in a given pacing mode independent of
time, they often do not reflect the whole truth. In our study, for ex-
ample, Kaplan–Meier analysis suggests that Biotronik CRT-Ds have
by far the best performance, but the analysis with regard to tem-
poral trends gives another picture. Here, Biotronik is in the range
of Medtronic and by far behind Boston Scientific. The poor per-
formance of most Medtronic and Boston Scientific CRT-Ds in the
first half of the study period leads to this distorted result.
Temporal trends

The comparison of longevity at 6 years of ICDs implanted before and after 2006 shows first and foremost an absolute increase in longevity of 10% (DDD) and 20% (VVI & CRT), yet differences between manufacturers exist regarding absolute values. In contemporary VVI-ICDs, Boston Scientific excelled with 100% longevity at 6 years, Biotronik was subprime with 50% longevity, and the other manufacturers were satisfactory. In DDD pacing mode, Biotronik and St. Jude Medical were subprime, Sorin and Medtronic moderate, and again Boston Scientific excelled. The most remarkable difference was seen in CRT-Ds, with Boston Scientific again showing an almost 100% longevity at 6 years compared with all other manufacturers with St. Jude Medical being at the tail end with only 26% longevity. This poor performance seems at first glance contradictory to data from the study of Alam et al. in which St. Jude Medical longevity at 4 years was reported as 92%. At second glance, these results are hampered as they depend only on 57 implanted CRTs and actually four replacements.

Temporal trends have been analysed with a cut-off in the year 2002. In two studies, no significant improvement was observable. In one study, mean longevity of replaced devices improved by 12 months in DDD and CRT and by 20 months in VVI pacing mode. The value of these results is altogether hampered by a severe dysbalance between groups (only 12% of ICDs were implanted before 2002).

The difference among manufacturers in the second half of the study period and the striking improvement in longevity in all Boston Scientific ICD pacing modes might be due to their specific battery technology. Boston Scientific incorporates a Lithium Manganese battery with a capacity of almost 2 ampere-hours in their contemporary devices, whereas other manufacturers usually use Lithium Silver Vanadium with less ampere-hours. Further studies are needed to confirm or repudiate this hypothesis.

Longevity and survival

Only one paper described the interrelation of longevity and survival. In 2005, Hauser reported a 4-year survival of 79% and refers to unpublished data with 4-year longevity of 54%. While survival is pretty similar to the present study (here 83.3%), a huge difference exists regarding longevity (here 85.1%). This can be explained, at least in part, by the temporal trend of increased longevity. However, it is intriguing that also in newer ICDs, 5-year survival is still better than 5-year longevity. While the difference was only 5% in VVI-ICDs (and thus acceptable), it rose to 15% in DDD-ICDs. In CRT-ICDs implanted in an admittedly high-risk population with a higher mortality, the difference was 23%. This indicates that a better battery technology is foremost required for this group of patients.

Impact of the number of shocks, pacing percentage, and pacing thresholds

We could not perform special analyses with regard to these possible confounders as they were available only in a minority of devices. Previous studies negated a significant influence of shocks on longevity. Pacing percentage and thresholds have been shown to be different in between manufacturers, but only when all ICDs were grouped together and not in different pacing modes. Predictors of decreased longevity were the LV output per se, an increase in overall pacing output of 1 V, and a 10% increase in pacing percentage, but no analyses were performed to show that they were different among manufacturers. A limitation of these analyses is the fact that only values determined at last follow-up were considered, thus giving a skewed picture of reality with the use of a random point in time. In addition, all these possible confounders probably are smoothed by the large number of devices included in the present study.
Limitations
This study has the inherent limitations of all registry data. An attribution bias (the physician could implant a presumed long-lasting ICD in a young patient and vice versa) might be present but is limited by the two-centre design of the study and consequently different perceptions and daily practice. Implantable cardioverter defibrillators were replaced at ERI and longevity calculated according to it and not to the end of life of the battery, thus reducing the real longevity. However, this was done in all studies on longevity so far. As all ICDs implanted in both centres were included over a long period of time, some results do not reflect longevity of currently available and implanted ICDs. However, this is overcome in part by the separate analysis on temporal trends according to the median time of implant. If one wants to have data on longevity of rather long-lasting devices, requesting results that reflect longevity of ICDs implanted in the past few years is an obvious oxymoron.

Conclusion
At 5 years, overall ICD longevity is 70% and thus lower than the patient survival of 80%. A highly significant improvement of longevity was seen in more contemporary models implanted after 2006. However, this improvement was unequal among the manufacturers. Results might impact on device selection.

Supplementary material
Supplementary material is available at Europace online.
Acknowledgements
The authors would like to thank Mrs Rehana Huber, MD, and Mr Brian Lauder Bethell MSc & MBA for their invaluable help in editing the manuscript.

Conflict of interest: B.A.S.: Medtronic: speaker bureau; C.S.: Biotronik: speaker bureau, consultant, investigator, research funding; Boston Scientific: investigator; Medtronic: investigator, advisory board; Sorin: speaker bureau, consultant. M.K.: Medtronic: proctor. S.O.: Biotronik: educational grants; Boston Scientific: educational grants; Medtronic: educational grants; Sorin: educational grants; St. Jude Medical: educational grants. D.A.M.J.T.: Biotronik: research funding; Boston Scientific: research funding, consultant.

References
1. Eckstein J, Koller MT, Zabel M, Kalusche D, Schaer BA, Osswald S et al. Necessity for surgical revision of defibrillator leads implanted long-term: causes and management. Circulation 2008;117:2727–33.
2. Fisher JD, Koulogianni KP, Lewallen L, Katz D, Kim SG, Ferrick KJ et al. The psychological impact of implantable cardioverter-defibrillator recalls and the durable positive effects of counseling. Pacing Clin Electrophysiol 2009;32:1012–6.
3. Lee DS, Krah AD, Hesley JS, Birne D, Crystal E, Dorian P et al. Evaluation of early complications related to De Novo cardioverter defibrillator implantation insights from the Ontario ICD database. J Am Coll Cardiol 2010;55:774–82.
4. Pedersen SS, Sears SF, Burg MM, Van den Broek KC. Does ICD indication affect quality of life and levels of distress? Pacing Clin Electrophysiol 2009;32:153–6.
5. Pedersen CT, Kay GN, Kalman J, Borggreve M, Della-Bella P, Dickfeld T et al. EHRA/HRS/APHRS expert consensus on ventricular arrhythmias. Europace 2014;16:1257–83.
6. Pedersen SS, van den Broek KC, Erdman RA, Jordaens L, Theuns DA. Pre-implantation implantable cardioverter defibrillator concerns and Type D personality increase the risk of mortality in patients with an implantable cardioverter defibrillator. Europace 2010;12:1446–52.
7. Ruwald AC, Schuger C, Moss AJ, Kuttyva F, Olshansky B, Greenberg H et al. Mortality reduction in relation to implantable cardioverter defibrillator programming in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT). Circ Arrhythmia and electrophysiol 2014;7:785–92.
8. Klug D, Lacroix D, Savoye C, Gouillard L, Grandmougin D, Hennequin J et al. Systemic infection related to endocarditis on pacemaker leads: clinical presentation and management. Circulation 1997;95:2098–107.
9. Polyzos KA, Kontantelias AA, Falagas ME. Risk factors for cardiac implantable electronic device infection: a systematic review and meta-analysis. Europace 2015;17:767–77.
10. Alam MB, Munir MB, Rattan R, Flanagan S, Adelstein E, Jain S et al. Battery longevity in cardiac resynchronization therapy implantable cardioverter defibrillators. Europace 2014;16:246–51.
11. Biffi M, Ziacchi M, Bertini M, Sangiorgi D, Corsini D, Martignani C et al. Longevity of implantable cardioverter-defibrillators: implications for clinical practice and health care systems. Europace 2008;10:1288–95.
12. Hauser RG. The growing mismatch between patient longevity and the service life of implantable cardioverter-defibrillators. J Am Coll Cardiol 2005;45:2022–5.
13. Horibeck FW, Mellert F, Kreuz J, Nickenig G, Schwab JO. Real-world data on the lifespan of implantable cardioverter-defibrillators depending on manufacturers and the amount of ventricular pacing. J Cardiovasc Electrophysiol 2012;23:1336–42.
14. Knops P, Theuns DA, Res JC, Jordaens L. Analysis of implantable defibrillator longevity under clinical circumstances: implications for device selection. Circulation 2009;117:1276–85.
15. Scher BA, Koller MT, Sticherling C, Altmann D, Joerg L, Osswald S. Longevity of implantable cardioverter-defibrillators, influencing factors, and comparison to industry-projected longevity. Heart Rhythm 2009;6:1737–43.
16. Shafat T, Baumfeld Y, Novack V, Konstantino Y, Amit G. Significant differences in the expected versus observed longevity of implantable cardioverter defibrillators (ICDs). Clin Res Cardiol 2013;102:43–9.
17. Siontis KC, Pantos I, Katrisis DG. Comparison of the longevity of implantable cardioverter-defibrillator devices by different manufacturers. Int J Cardiol 2014;175:380–2.
18. Thijssen J, Borleffs CJ, van Rees JB, Man S, de Bie MK, Venlet JJ et al. Implantable cardioverter-defibrillator longevity under clinical circumstances: an analysis according to device type, generation, and manufacturer. Heart Rhythm 2012;9:513–9.
19. Landolina M, Curnis A, Morani G, Vado A, Ammendola E, D’ionorio A et al. Longevity of implantable cardioverter-defibrillators for cardiac resynchronization therapy in current clinical practice: an analysis according to influencing factors, device generation, and manufacturer. Europace 2015;17:1251–8.
20. Boriani G, Braunschweig F, Deharo JC, Leyva F, Lubinski A, Lazzaro C. Impact of extending device longevity on the long-term costs of implantable cardioverter-defibrillator therapy: a modelling study with a 15-year time horizon. Europace 2013;15:1453–62.